4.5 Article

Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry Study

Journal

LUNG CANCER
Volume 64, Issue 2, Pages 232-237

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2008.08.005

Keywords

Lung neoplasms; Registries; Epidemiology; Survival; Korea

Ask authors/readers for more resources

Purpose and methods: The outcomes of lung cancer patients who were asymptomatic at diagnosis have never been reported as part of a large-scale study. A national survey of lung cancer in South Korea registered a total of 8788 patients diagnosed in 2005. We report the results herein, with an emphasis on the prognosis of the asymptomatic lung cancer patients. Results: Adenocarcinoma was the most frequent (36.1%) histopathologic type, followed by squamous cell carcinoma (32.1%), large cell carcinoma (1.5%), and small cell carcinoma (13.5%). In most cases, lung cancer was detected with subjective symptoms, but 6.5% of cases had no symptoms indicative of lung cancer at the time of diagnosis. Compared to symptomatic patients, asymptomatic patients were younger, more often female, non-smokers, and more frequently presented with adenocarcinoma. Initial treatments were surgery (22.1%), radiation therapy (7.8%), chemo-radiation therapy (5.4%), and chemotherapy (38%), while 26.6% of patients were recorded to have supportive care only. Asymptomatic patients received surgery in 60.0% of cases, and they showed significantly longer survival times than symptomatic patients. Absence of symptoms at diagnosis significantly reduced the risk of death from non-small cell lung cancer, regardless of patient age, patient gender, stage at diagnosis, smoking history, or whether treatment was performed, but did not reduce the risk of death from small cell lung cancer. Conclusions: Adenocarcinoma has grown to be the leading histopathologic type of lung cancer in South Korea. Absence of symptom at diagnosis is a favorable prognostic factor for patients with non-small cell lung cancer. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic significance of location index in resected T1-sized early-stage non-small cell lung cancer

Seung Wan Kang, Won Gi Jeong, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Byung Chan Lee, Yun-Hyeon Kim

Summary: This study aimed to determine the prognostic significance of central lung cancer in resected T1-sized early-stage non-small cell lung cancer (NSCLC). The results showed that central lung cancer, defined by a location index, was adversely associated with relapse-free survival and overall survival. It was found to be an independent adverse prognostic factor in early-stage NSCLC.

ACTA RADIOLOGICA (2023)

Article Allergy

Impacts of Asthma in Patients With Bronchiectasis: Findings From the KMBARC Registry

Seong Mi Moon, Hayoung Choi, Hyung Koo Kang, Sei Won Lee, Yun Su Sim, Hye Yun Park, Yong-Soo Kwon, Sang-Heon Kim, Yeon-Mok Oh, Hyun Lee

Summary: This study evaluated 598 patients from the Korean Bronchiectasis Registry and found that bronchiectasis patients with asthma had higher BMI, more dyspnea, larger sputum volume, and lower FEV1 than those without asthma. Asthma was also associated with lower quality of life. Therefore, understanding the impacts of asthma in bronchiectasis is crucial for appropriate management.

ALLERGY ASTHMA & IMMUNOLOGY RESEARCH (2023)

Article Pharmacology & Pharmacy

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study

Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal, Jin Woo Song

Summary: This study evaluated the impact of reduced dose of pirfenidone on clinical outcomes in patients with IPF. The results showed that reduced doses did not have a negative impact on clinical outcomes compared to standard-dose pirfenidone, suggesting that dose reduction may be a useful method to manage adverse events while maintaining therapeutic efficacy.

FRONTIERS IN PHARMACOLOGY (2023)

Article Oncology

A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh

Summary: In this retrospective cohort study, durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) was found to be associated with survival benefits in real-world contexts, supporting its establishment as a new standard of care for stage III NSCLC. The study aimed to provide real-world evidence regarding the effectiveness and safety of DC after CCRT in the treatment of unresectable stage III NSCLC.

CANCERS (2023)

Article Oncology

Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments

Gowoon Yang, Chang Young Lee, Eun Young Kim, Chang Geol Lee, Min Hee Hong, Byung Jo Park, Hong In Yoon, Kyung Hwan Kim, Sang Hoon Lee, Hwa Kyung Byun, Jaeho Cho

Summary: This study aimed to determine the role of radiotherapy (RT) and the optimal RT target volume in the treatment of thymic carcinoma. A total of 116 patients who received multimodal treatment were included. The target volume was defined as the tumor bed or gross tumor with margin, and selective irradiation of the regional nodal area was performed when involved. The results showed a high local control rate with RT, and a target volume confined to the tumor bed or gross tumor plus margin with the involved lymph node stations seems reasonable.

CANCERS (2023)

Article Oncology

Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Cheol-Kyu Park, Sung-Woo Lee, Hyun-Ju Cho, Hyung-Joo Oh, Young-Chul Kim, Yong-Hyub Kim, Sung-Ja Ahn, Jae-Ho Cho, In-Jae Oh

Summary: A total of 50 patients with unresectable stage III NSCLC who received CCRT between March 2020 and March 2021 were recruited. Durvalumab consolidation (DC) was administered to patients (n=23) without progression after CCRT and programmed death-ligand 1 (PD-L1) ≥1%. Blood samples collected before (C0) and after CCRT (C1) were analyzed to calculate PBC counts and examine CTCs. The study found that the presence of residual CTC clusters at C1 and high platelet counts at C1 (PLThi) were independent risk factors for worse progression-free survival (PFS). The study suggests that the clearance of CTC clusters and platelet counts at C1 could serve as potential biomarkers for predicting survival.

CANCERS (2023)

Article Cell Biology

Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial

Cheol-Kyu Park, Ha Ra Jun, Hyung-Joo Oh, Ji-Young Lee, Hyun-Ju Cho, Young-Chul Kim, Jeong Eun Lee, Seong Hoon Yoon, Chang Min Choi, Jae Cheol Lee, Sung Yong Lee, Shin Yup Lee, Sung-Min Chun, In-Jae Oh

Summary: This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). The results suggest that baseline levels and dynamic changes of blood-based biomarkers can predict atezolizumab efficacy in previously treated NSCLC patients.

CELLS (2023)

Article Oncology

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib

Ha-Young Park, Joo-Heon Park, Myung-Geun Shin, Seung Jung Han, Yong-Sok Ji, Hyung-Joo Oh, Young-Chul Kim, Taebum Lee, Yoo-Duk Choi, In-Jae Oh

Summary: This case report presents a rare case of ultra-late recurrence of NSCLC with choroidal metastasis and KIF13A-RET fusion in a 48-year-old female never-smoker. The patient had undergone lobectomy followed by adjuvant chemotherapy 14 years prior. Choroidal metastatic lesions were observed, along with bone and uterine metastases. Liquid-based NGS confirmed the presence of KIF13A-RET fusion, and the patient showed a partial response to selpercatinib therapy.

FRONTIERS IN ONCOLOGY (2023)

Letter Oncology

Role of adjuvant treatment in stage IB non-small cell lung carcinoma

Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim

TRANSLATIONAL LUNG CANCER RESEARCH (2023)

Letter Cardiac & Cardiovascular Systems

Prognostic Impact of Intravascular Imaging-Guided Percutaneous Coronary Intervention in Chronic Total Occlusion

David Hong, Sang Min Kim, Sang Yeub Lee, Ki Hong Choi, Young Bin Song, Jong-Young Lee, Seung-Jae Lee, Kyeong Ho Yun, Jae Young Cho, Chan Joon Kim, Hyo-Suk Ahn, Chang-Wook Nam, Hyuck-Jun Yoon, Yong Hwan Park, Wang Soo Lee, Jin-Ok Jeong, Pil Sang Song, Joon-Hyung Doh, Sang-Ho Jo, Chang-Hwan Yoon, Min Gyu Kang, Jin-Sin Koh, Kwan Yong Lee, Young-Hyo Lim, Yun-Hyeong Cho, Jin-Man Cho, Woo Jin Jang, Kook-Jin Chun, Taek Kyu Park, Jeong Hoon Yang, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn, Joo Myung Lee

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

QFR Assessment and Prognosis After Nonculprit PCI in Patients With Acute Myocardial Infarction

Seung Hun Lee, David Hong, Doosup Shin, Hyun Kuk Kim, Keun Ho Park, Eun Ho Choo, Chan Joon Kim, Min Chul Kim, Young Joon Hong, Sung Gyun Ahn, Joon-Hyung Doh, Sang Yeub Lee, Sang Don, Hyun-Jong Lee, Min Gyu Kang, Jin-Sin Koh, Yun-Kyeong Cho, Chang-Wook Nam, Hyun Sung Joh, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Seung-Hyuk Choi, Myung Ho Jeong, Hyeon-Cheol Gwon, Joo-Yong Hahn, Joo Myung Lee

Summary: In AMI patients with multivessel disease, 30.0% of angiography-guided PCI resulted in un-necessary PCI for the non-IRA with QFR >0.80, which was significantly associated with an increased risk of MACEs than in those with deferred PCI for non-IRA lesions.

JACC-CARDIOVASCULAR INTERVENTIONS (2023)

Article Oncology

Healthcare utilization of lung cancer patients associated with exposure to fine particulate matter: A Korean cohort study

In-Jae Oh, Cheol-Kyu Park, Kyoung-Bok Min, Jin-Young Min, Chaeuk Chung, Seong-Hoon Yoon, Changsoo Kim, Sei-Hoon Yang

Summary: A study in Korea found that lung cancer patients exposed to high concentrations of PM2.5 had significantly increased healthcare utilization and drug prescriptions.

THORACIC CANCER (2023)

Article Medicine, General & Internal

Intracranial Efficacy of Systemic Therapy in Patients with Asymptomatic Brain Metastases from Lung Cancer

Min-Gwan Sun, Sue Jee Park, Yeong Jin Kim, Kyung-Sub Moon, In-Young Kim, Shin Jung, Hyung-Joo Oh, In-Jae Oh, Tae-Young Jung

Summary: There is ongoing controversy regarding whether to use radiologic follow-up or local treatment for asymptomatic small-sized brain metastases from primary lung cancer. This study evaluated the potential factors related to brain progression and the effectiveness of systemic therapy in controlling tumors without local treatment. The results showed that targeted therapy was superior to cytotoxic chemotherapy in the treatment of these brain metastases, offering the opportunity to determine the optimal timing for local treatment while reducing the risk of brain-related mortality.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection

Hwa Kyung Park, Yoo Duk Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Young Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh

Summary: This study investigated the prevalence of genetic alterations in early-stage non-small cell lung cancer (NSCLC) and the association between EGFR mutations and recurrence after surgical resection. The presence of EGFR mutations was found to be an independent risk factor for recurrence and was associated with systemic recurrence. Targeted therapy should be considered more actively as an adjuvant or neoadjuvant treatment option.

CANCERS (2023)

Article Oncology

Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)

Wonjun Ji, In-Jae Oh, Cheol-Kyu Park, Sung Yong Lee, Juwhan Choi, Jae Cheol Lee, Jiwon Kim, Seung Hyeun Lee

Summary: This study provides real-world evidence of the effectiveness and safety of afatinib as a treatment option for patients with squamous cell carcinoma of the lung (LSCC) who have progressed after chemotherapy and immunotherapy. The study also highlights the potential predictive value of the ERBB2 mutation as a biomarker in clinical settings.

CANCERS (2023)

No Data Available